Parathyroid Hormone: A Uremic Toxin

Overview

Journal Toxins (Basel)

Publisher MDPI

Specialty Toxicology

Date 2020 Mar 21

PMID 32192220

Citations 27

Authors

Eduardo J Duque

Rosilene M Elias

Rosa M A Moyses

Affiliations

Soon will be listed here.

Abstract

Parathyroid hormone (PTH) has an important role in the maintenance of serum calcium levels. It activates renal 1α-hydroxylase and increases the synthesis of the active form of vitamin D (1,25[OH]D). PTH promotes calcium release from the bone and enhances tubular calcium resorption through direct action on these sites. Hallmarks of secondary hyperparathyroidism associated with chronic kidney disease (CKD) include increase in serum fibroblast growth factor 23 (FGF-23), reduction in renal 1,25[OH]D production with a decline in its serum levels, decrease in intestinal calcium absorption, and, at later stages, hyperphosphatemia and high levels of PTH. In this paper, we aim to critically discuss severe CKD-related hyperparathyroidism, in which PTH, through calcium-dependent and -independent mechanisms, leads to harmful effects and manifestations of the uremic syndrome, such as bone loss, skin and soft tissue calcification, cardiomyopathy, immunodeficiency, impairment of erythropoiesis, increase of energy expenditure, and muscle weakness.

Citing Articles

Chronic Kidney Disease and Osteoarthritis: Current Understanding and Future Research Directions.

Yang R, Chan D, Chung Y, Liu S Int J Mol Sci. 2025; 26(4).

PMID: 40004032 PMC: 11854965. DOI: 10.3390/ijms26041567.

Calcium to magnesium ratio as a superior biomarker for nephrolithiasis detection in primary hyperparathyroidism.

Yalcin N, Ertinmaz Ozkan A, Gunes E, Koca N Sci Rep. 2025; 15(1):3545.

PMID: 39875421 PMC: 11775213. DOI: 10.1038/s41598-025-86954-4.

Short and long-term effects of kidney donation on mineral and bone metabolism.

Duque E, Ferreira G, Oliveira I, Dominguez W, Agena F, Jorgetti V BMC Nephrol. 2024; 25(1):381.

PMID: 39462348 PMC: 11514742. DOI: 10.1186/s12882-024-03827-0.

Beyond Numbers: How Biochemical Parameters Can Predict Outcomes in Chronic Kidney Disease Patients on Maintenance Hemodialysis.

Siddiqui I, Masood A, Chandagiri S, Kumar R, Mir A Cureus. 2024; 16(8):e67349.

PMID: 39310569 PMC: 11413472. DOI: 10.7759/cureus.67349.

The role of osteopontin and osteocyte-derived factors in secondary hyperparathyroidism-induced myopathy.

Duque E, Crispilho S, Oliveira I, Dominguez W, Silva C, Furukawa L JBMR Plus. 2024; 8(8):ziae084.

PMID: 39070237 PMC: 11273725. DOI: 10.1093/jbmrpl/ziae084.

References

Khajehdehi P, Ali M, Henry G, Bastani B . The effects of parathyroidectomy on nutritional and biochemical status of hemodialysis patients with severe secondary hyperparathyroidism. J Ren Nutr. 1999; 9(4):186-91. DOI: 10.1016/s1051-2276(99)90032-8. View

Hofbauer L, Brueck C, Shanahan C, Schoppet M, Dobnig H . Vascular calcification and osteoporosis--from clinical observation towards molecular understanding. Osteoporos Int. 2006; 18(3):251-9. DOI: 10.1007/s00198-006-0282-z. View

Hory B, Roussanne M, Rostand S, Bourdeau A, Drueke T, Gogusev J . Absence of response to human parathyroid hormone in athymic mice grafted with human parathyroid adenoma, hyperplasia or parathyroid cells maintained in culture. J Endocrinol Invest. 2000; 23(5):273-9. DOI: 10.1007/BF03343723. View

Martin A, David V, Quarles L . Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev. 2012; 92(1):131-55. PMC: 3306265. DOI: 10.1152/physrev.00002.2011. View

Heyliger A, Tangpricha V, Weber C, Sharma J . Parathyroidectomy decreases systolic and diastolic blood pressure in hypertensive patients with primary hyperparathyroidism. Surgery. 2009; 146(6):1042-7. PMC: 2845911. DOI: 10.1016/j.surg.2009.09.024. View

Da J, Xie X, Wolf M, Disthabanchong S, Wang J, Zha Y . Serum Phosphorus and Progression of CKD and Mortality: A Meta-analysis of Cohort Studies. Am J Kidney Dis. 2015; 66(2):258-65. DOI: 10.1053/j.ajkd.2015.01.009. View

Noda M, Camilliere J . In vivo stimulation of bone formation by transforming growth factor-beta. Endocrinology. 1989; 124(6):2991-4. DOI: 10.1210/endo-124-6-2991. View

Goto S, Fujii H, Hamada Y, Yoshiya K, Fukagawa M . Association between indoxyl sulfate and skeletal resistance in hemodialysis patients. Ther Apher Dial. 2010; 14(4):417-23. DOI: 10.1111/j.1744-9987.2010.00813.x. View

Olauson H, Lindberg K, Amin R, Sato T, Jia T, Goetz R . Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion. PLoS Genet. 2013; 9(12):e1003975. PMC: 3861040. DOI: 10.1371/journal.pgen.1003975. View

10.

Mace M, Gravesen E, Nordholm A, Hofman-Bang J, Secher T, Olgaard K . Kidney fibroblast growth factor 23 does not contribute to elevation of its circulating levels in uremia. Kidney Int. 2017; 92(1):165-178. DOI: 10.1016/j.kint.2017.01.015. View

11.

Picton M, Moore P, Mawer E, Houghton D, Freemont A, Hutchison A . Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int. 2000; 58(4):1440-9. DOI: 10.1046/j.1523-1755.2000.00306.x. View

12.

Conigrave A . The Calcium-Sensing Receptor and the Parathyroid: Past, Present, Future. Front Physiol. 2016; 7:563. PMC: 5156698. DOI: 10.3389/fphys.2016.00563. View

13.

Fukagawa M, Kazama J, Shigematsu T . Skeletal resistance to pth as a basic abnormality underlying uremic bone diseases. Am J Kidney Dis. 2001; 38(4 Suppl 1):S152-5. DOI: 10.1053/ajkd.2001.27426. View

14.

Workeneh B, Mitch W . Review of muscle wasting associated with chronic kidney disease. Am J Clin Nutr. 2010; 91(4):1128S-1132S. DOI: 10.3945/ajcn.2010.28608B. View

15.

Neves K, Graciolli F, Reis L, Graciolli R, Neves C, Magalhaes A . Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int. 2007; 71(12):1262-70. DOI: 10.1038/sj.ki.5002241. View

16.

Jorde R, Sundsfjord J, Haug E, Bonaa K . Relation between low calcium intake, parathyroid hormone, and blood pressure. Hypertension. 2000; 35(5):1154-9. DOI: 10.1161/01.hyp.35.5.1154. View

17.

Jiang X, Kanai H, Shigehara T, Maezawa A, Yano S, Naruse T . Metabolism of transforming growth factor-beta in patients receiving hemodialysis especially those with renal osteodystrophy. Ren Fail. 1998; 20(1):135-45. DOI: 10.3109/08860229809045096. View

18.

Pettway G, Schneider A, Koh A, Widjaja E, Morris M, Meganck J . Anabolic actions of PTH (1-34): use of a novel tissue engineering model to investigate temporal effects on bone. Bone. 2005; 36(6):959-70. DOI: 10.1016/j.bone.2005.02.015. View

19.

. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42(4 Suppl 3):S1-201. View

20.

Iwasaki-Ishizuka Y, Yamato H, Nii-Kono T, Kurokawa K, Fukagawa M . Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone. Nephrol Dial Transplant. 2005; 20(9):1904-11. DOI: 10.1093/ndt/gfh876. View